Back to search
Cancer of Unknown Primary Site
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer of Unknown Primary Site trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer of Unknown Primary Site trials you may qualify forThis phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell c…
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hear…
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation…
This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to sw…
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with…
This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage I…
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipil…